Esperion Therapeutics Inc.
NEWS
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
Esperion today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:
Esperion today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2018.
Shares of Ann Arbor, Mich.-based Esperion Therapeutics are up more than 7 percent in premarket trading after the company announced on Sunday that planned to seek regulatory approval for its cholesterol-lowering therapy that hit the mark in a Phase III trial.
Ann Arbor, Mich.-based Esperion Therapeutics is starting off the week with several positives. The company first reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year.
JOBS
IN THE PRESS